PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES- THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE
Abstract
Authors
J Gaultney M Franken CWM van Gils P Huijgens WK Redekop CA Uyl-de Groot